Injectable opioid agonist therapy, extended-release agonists, and antagonists are beyond the scope of this guideline. "The management of opioid use disorder is a rapidly changing and ever-evolving ...

Opioid-related neurocognitive symptoms among patients on long-term opioid therapy were most prevalent during the course of therapy.

and willingness to continue opioid therapy. A literature search identified more than a dozen published reports on the use of pure opioid antagonists (naloxone, naltrexone, methylnaltrexone ...

The global burden of anxiety- and depression-related disorders is on the rise. While multiple drugs have been developed to treat these conditions, current medications have several limitations, ...

The latest volunteer-run overdose prevention site to open is outside North Island Hospital Comox Valley on Vancouver Island.

Cebranopadol is an investigational dual-nociceptin/orphanin FQ peptide receptor and µ-opioid peptide receptor agonist.

App users also stayed with their opioid agonist therapy an average 290 days, compared with 236 days for those who only got medication, the study says. “These results are promising, and they ...

The research, led by medical anthropologist Jennifer Carroll, found that only 7 of 94 identified residential treatment providers in North Carolina offer Opioid Agonist Treatment (OAT)—a proven ...

Researchers from Tokyo University of Science uncover cellular and molecular mechanisms underlying the antidepressant-like effects of the delta opioid receptor agonists, paving the way for its ...

The prevalence of substance use disorders, such as opioid and alcohol use disorders ... link between glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as Ozempic, and reductions in ...